AstraZeneca announced that it has completed the acquisition of the core respiratory business of Takeda Pharmaceutical Company Limited . The agreement, announced in December 2015, includes the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease. AstraZeneca has marketed Daliresp in the US since the acquisition of the rights from Actavis in the first quarter of 2015.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology – as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries
Neil BurrowsUK/Global
+44 20 7604 8032 Vanessa Rhodes
UK/Global
+44 20 7604 8037 Karen Birmingham
UK/Global
+44 20 7604 8120 Jacob Lund
Sweden
+46 8 553 260 20
Abigail Bozarth US
+1 302 885 2677
Investor Enquiries
UK
Thomas Kudsk LarsenOncology
+44 7818 524185
Eugenia Litz
RIA
+44 7884 735627
Nick Stone
CVMD
+44 7717 618834
Craig Marks
Finance
+44 7881 615764
Christer Gruvris
Consensus Forecasts
+44 7827 836825
US
Lindsey TrickettOncology, ING
+1 240 543 7970
Mitch Chan
Oncology
+1 240 477 3771
Dial / Toll-Free
+1 866 381 7277
